Figure 3. Dasatinib has an additive effect with common therapeutic drugs in NSCLC but not SCLC cells.

(A and B) A549 (A) or H510 and H69 cells (B) were treated with or without 30 nM (A) or 1 μM dasatinib (DAS) and increasing concentrations of etoposide, cisplatin or paclitaxel. Cell growth was monitored by crystal violet (A) or WST-1 assay (B) 48 h later. Graphs represent means ± SEM from three independent experiments performed in triplicate and normalised to control. Statistical analysis was performed using ANOVA (^*p < 0.05, ^**p < 0.01, ^***p < 0.005).